Méndez‐Flores, SilviaSilviaMéndez‐FloresPriego‐Ranero, ÁngelÁngelPriego‐RaneroAzamar‐Llamas, DanielDanielAzamar‐LlamasOlvera‐Prado, HéctorHéctorOlvera‐PradoRivas‐Redonda, Kenia IlianKenia IlianRivas‐RedondaOchoa‐Hein, EricEricOchoa‐HeinRojas‐Castañeda, EstefanoEstefanoRojas‐CastañedaUrbina‐Terán, SaidSaidUrbina‐TeránSeptién‐Stute, LuisLuisSeptién‐StuteHernández‐Gilsoul, ThierryThierryHernández‐GilsoulAguilar‐Morgan, Adrián AndrésAdrián AndrésAguilar‐MorganFernández‐Camargo, Dheni A.Dheni A.Fernández‐CamargoOlivares‐Martínez, ElizabethElizabethOlivares‐MartínezHernández‐Ramírez, Diego F.Diego F.Hernández‐RamírezTorres‐Villalobos, GonzaloGonzaloTorres‐VillalobosFuruzawa-Carballeda, JanetteJanetteFuruzawa-Carballeda2022-11-242022-11-242022https://scripta.up.edu.mx/handle/20.500.12552/218410.1002/ctm2.763Dear Editor: Although dexamethasone is approved for the hyperinflammation treatment of hospitalised COVID-19 patients, non-hospitalised patients do not benefit from this therapy.1 A potential drug for treating COVID-19 patients is polymerised type I collagen (PTIC). A downregulator of pro-inflammatory cytokines, adhesion molecules (ELAM-1, VCAM-1, and ICAM-1), cyclooxygenase (Cox)-1 enzyme and the collagenases expression through the modulation of transcription of factor NF-kB.2-6 The intramuscular or subcutaneous administration of PTIC to patients with active RA (Phase II studies) improved the count of swollen joints and morning stiffness; 57% of patients achieved an ACR score of 50, and 30% had disease remission with this therapeutic combination. PTIC was safe and well-tolerated in long-term treatment, without adverse effects. © Clinical and Translational MedicineenResource Types::text::journal::letter to the editor